# Akebia Therapeutics to Report First Quarter 2026  Financial Results and Discuss Recent Business Highlights
Canonical URL: https://biopharmsignal.com/news/AKBA/akebia-therapeutics-to-report-first-quarter-2026-financial-results-and-discuss-r-fb91dbfe
Ticker: AKBA
Company: Akebia Therapeutics
Source: Akebia Therapeutics
Published: 2026-04-30 20:05 EST
## Summary

Akebia to Host Conference Call on May 7 at 8:00 a.m. EDT CAMBRIDGE, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA)...

## Article Body
Akebia to Host Conference Call on May 7 at 8:00 a.m. EDT

CAMBRIDGE, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the first quarter ended March 31, 2026 on Thursday, May 7, 2026, prior to the open of financial markets.

Akebia will host a conference call on Thursday, May 7, 2026, at 8:00 a.m. EDT to discuss its financial results and recent business highlights. To access the call, please register by clicking on this Registration Link , and you will be provided with dial in details. To avoid delays and ensure timely connection, we encourage dialing into the conference call 15 minutes ahead of the scheduled start time.

A live webcast of the conference call will be available via the Investors section of Akebia’s website at: https://ir.akebia.com/ . An online archive of the webcast can be accessed via the Investors section of Akebia’s website at http://ir.akebia.com .

About Akebia Therapeutics Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact Mercedes Carrasco mcarrasco@akebia.com
## Recent Company News
- 2026-07-02 20:05 EST — [Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/AKBA/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bc8c2359) — Source: Akebia Therapeutics
- 2026-06-30 12:00 EST — [U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA](https://biopharmsignal.com/news/AKBA/u-s-renal-care-and-akebia-announce-interim-analysis-of-voice-trial-demonstrated--7cc9c9bc) — Source: Akebia Therapeutics
- 2026-06-10 12:00 EST — [Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio](https://biopharmsignal.com/news/AKBA/akebia-therapeutics-strengthens-vafseo-vadadustat-patent-portfolio-17cb62c9) — Source: Akebia Therapeutics
- 2026-06-01 20:05 EST — [Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/AKBA/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eb3ccebf) — Source: Akebia Therapeutics
- 2026-05-28 12:00 EST — [Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/AKBA/akebia-therapeutics-to-present-at-the-2026-jefferies-global-healthcare-conferenc-a2e97fe3) — Source: Akebia Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)